✦ LIBER ✦

Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy

✍ Scribed by Hiroshi Miyata; Akiko Yoshioka; Makoto Yamasaki; Yoichiro Nushijima; Shuji Takiguchi; Yoshiyuki Fujiwara; Toshiro Nishida; Masayuki Mano; Masaki Mori; Yuichiro Doki

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 290 KB
Volume: 115
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24390

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Neoadjuvant chemotherapy followed by tum

Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma

✍ Walther Kuhn; Stefan Rutke; Kerstin Späthe; Barbara Schmalfeldt; Gerd Florack; B 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 1 views

High expression of EZH2 is associated wi

High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy

✍ Li-Ru He; Meng-Zhong Liu; Bin-Kui Li; Wei-Hua Jia; Ying Zhang; Yi-Ji Liao; Yang- 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 498 KB 👁 1 views

## Abstract The enhancer of zeste homolog 2 (EZH2), a known repressor of gene transcription, has been reported to be associated with biological malignancy in several cancers. The potential oncogenic role of EZH2 and its clinical/prognostic significance, however, in esophageal squamous cell carcinom